Journal
PARKINSONISM & RELATED DISORDERS
Volume 33, Issue -, Pages S28-S35Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.parkreldis.2016.11.020
Keywords
Parkinson's disease; Apomorphine; Non-motor symptoms; Cognition; Amyloid
Categories
Funding
- UCB
- Britannia
- Bial
- US Worldmeds
- Medtronic
- Mundipharma
- Otsuka Pharmaceuticals
Ask authors/readers for more resources
Non-motor features have a great impact on progression and quality of life in individuals with Parkinson's disease. Current treatments for PD are limited and apomorphine is one of the advanced therapies available with advantageous effects on motor complications. Several studies have suggested that apomorphine has potential benefits in PD patients beyond its established role in the treatment of motor fluctuations and levodopa-induced dyskinesia. This review examines the efficacy of apomorphine in the treatment of non-motor symptoms (NMS), describing recent studies that highlight its possible effect on cognition. Despite a limited number of studies, the available evidence shows that apomorphine has an overall beneficial effect on NMS of PD patients, including neuropsychiatric symptoms, sleep disturbances, pain, urinary dysfunction, and impulse control disorders. If the effects of apomorphine on amyloid deposition are confirmed in the future, its place in the armamentarium of PD treatment could see a shift towards younger and non-demented PD patients. (C) 2016 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available